Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abnormal expression of MDM2 in prostate carcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 May 2001

Leite K R, Franco M F, Srougi M, Nesrallah L J, Nesrallah A, Bevilacqua R G, Darini E, Carvalho C M, Meirelles M I, Santana I, Camara-Lopes L H

Abstract excerpt

Mutation of p53 is rare in localized prostate carcinoma. The oncoprotein MDM2, whose gene has a response element for p53, promotes the degradation of p53 protein and inhibits its transcriptional activation of genes related to cell cycle arrest and apoptosis, constituting a negative feedback control. We studied p53 and MDM2 expression by immunohistochemistry and looked for mutations in p53 exons 5 to 8 by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, p53

Share to In Situ Nick-End Labeling

Share to Ki-67 Antigen

Share to Polymorphism, Single-Stranded Conformational

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 11353053
DOI: 10.1038/modpathol.3880330

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abnormal expression of MDM2 in prostate carcinoma.PMID 11353053Read ↗

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapySemantic proximity Read ↗

Alterations of p53 are common in early stage prostate cancer.Semantic proximity Read ↗

A clinical, pathologic, and molecular study of p53 and murine double minute 2 in penile carcinogenesis and its relation to prognosis.Semantic proximity Read ↗

Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cellsSemantic proximity Read ↗

Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancerSemantic proximity Read ↗

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3Semantic proximity Read ↗

Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.Semantic proximity Read ↗

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.Semantic proximity Read ↗

p53 gene alterations in human prostate carcinoma.Semantic proximity Read ↗

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.Semantic proximity Read ↗

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancerSemantic proximity Read ↗

Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.